Opinion|Videos|June 11, 2024
Recent Updates from MARIPOSA on Amivantamab Plus Lazertinib in EGFR-Mutated Advanced NSCLC
Joshua K. Sabari, MD, discusses recent updates from the MARIPOSA study, which is investigating amivantamab plus lazertinib in the first line in patients with EGFR-mutated advanced non–small cell lung cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Sunvozertinib is FDA approved for patients with NSCLC with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy.
Vopimetostat yielded favorable outcomes in a phase 1/2 trial in combination with daraxonrasib or zoldonrasib in MTAP-deleted, RAS-mutant pancreatic cancer or lung cancer.
Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Late-Breaking Phase 3 Data Headline ESMO 2026 Presidential Symposium I
2
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
3
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
4
Investigating Novel Immunotherapy Targets in Metastatic RCC
5